Brian Armstrong's NewLimit Raises $435M for Aging Drug Trials

NewLimit, a longevity biotech startup co-founded by Coinbase CEO Brian Armstrong, has raised $435 million in Series C funding to move its first age-reprogramming medicine toward human trials.

NewLimit announced the funding round on June 2, with Founders Fund leading the raise. New investors Thrive Capital, Greenoaks and Quiet Capital joined, while existing backers Kleiner Perkins, Abstract, Nat Friedman and Daniel Gross, Valor Equity Partners, Eli Lilly Ventures and Human Capital also participated. The company said it will use the funds to push its first aging reprogramming drug into human clinical trials next year.

"Following breakthrough results, we're bringing longevity medicine to human trials," NewLimit wrote in its announcement. "We've raised a $435M Series C led by @foundersfund to make it happen. Reprogramming cell age has the potential to create more healthy years for everyone. We're closer than ever to realizing it."

NewLimit focuses on epigenetic reprogramming, a method that aims to restore youthful function in old cells. The company says its medicines are designed to treat diseases linked to aging by changing how cells behave, without altering the DNA code itself. Its first program targets the liver. NewLimit said its liver therapy helped old human liver cells show signs of younger function in early research, and the company plans to test the approach in people during its first human trial.

NewLimit was founded in 2021 by Armstrong, former GV partner and bioengineer Blake Byers, and computational biologist Jacob Kimmel, who serves as chief executive and president. The company has become one of Armstrong's most visible projects outside Coinbase, where he still somehow finds time to run a major crypto exchange between longevity briefings. The raise also comes amid Armstrong's wider push into AI and automation, which crypto.news has tracked. Recent coverage noted Coinbase used AI to cut account restriction resolution times by 90%, while Armstrong has also flagged AI tools, stablecoins and tokenization as key finance upgrades.

The $435 million round places NewLimit among the better-funded private longevity startups — a category that, like crypto, seems to mint valuations based largely on future promises. The Wall Street Journal reported the raise lifted NewLimit's valuation to $3.1 billion, more than triple its level from last year. The company still has no approved product on the market, and its next test will come in human studies, where it must show that early cell-level results can translate into a safe and useful medicine. NewLimit said it originally believed bringing an aging medicine into human trials would take more than a decade, but now says recent scientific results helped it move faster than expected. The new capital will fund expansion across liver, immune, metabolic and vascular programs, giving Armstrong's biotech project a larger role in the growing longevity market.